uniQure N.V. (QURE)
Listed on NASDAQ • Healthcare / Biotechnology
Overview
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Explore More Data
Key Information
Symbol:
QURE
CEO:
Matthew Craig Kapusta CPA
Exchange:
NASDAQ
CIK:
0001590560
Website:
https://www.uniqure.com
SEC Filings:
View SEC →
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Price
26.06
Change
-4.38
Change %
-14.39%
Open
27.55
Previous Close
30.44
High
27.99
Low
25.52
Volume
8,893,476
Market Cap
1,605,394,304
EV/EBITDA
0
Capital Structure (Updated: Nov 05 04:00 PM EST)
Shares Outstanding
61,603,771
FloatShares
37,042,859
Float Ratio
60.13%
Shares Short
7,573,225
Short Percent Of Float
The percent of float shares currently sold short. Reflects market sentiment and risk of a short squeeze.
12.44%
Short Ratio
Days needed to cover all short positions. Indicates short-selling pressure.
1.09 trading days
Held Percent Insiders
5.41%
Held Percent Institutions
90.33%
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date (Estimated) | 2025-11-06 |
| Earnings Call (Estimated) | |
| Avg EPS Estimate | -0.7559 |
| Low EPS Estimate | -0.911 |
| High EPS Estimate | -0.536 |
| Revenue | |
| Avg Revenue Forecast | 4,456,920 |
| Low Revenue Forecast | 0 |
| High Revenue Forecast | 8,174,000 |
QURE Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $376,974,016 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 9.347 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 9.982 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $521,956,000 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
QURE Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $-146,439,008 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $-173,436,992 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $-111,588,128 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 0.00% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | -790.78% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 0.00% | Net profit margin, which reflects overall profitability. |
QURE Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 0.00% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $521,956,000 | Used together with cash and EBITDA to assess debt-paying ability. |
QURE Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | -52.70% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for QURE (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $26.06 | Latest stock trading price |
| Price Target (High) | $107.67 | Analyst highest expected price |
| Price Target (Low) | $37.89 | Analyst lowest expected price |
| Price Target (Average) | $70.34 | Average target price across analysts |
| Price Target (Median) | $70.48 | Median of target prices |
| Average Rating Score | 1.33 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | strong_buy | Consensus rating |
| Analyst Coverage Count | 10 | Number of analysts providing estimates |
| Cash Holdings | $376,974,016 | Total cash held by the company |
| Cash per Share | $6.87 | Cash value per outstanding share |
| Total Debt | $521,956,000 | Company's total debt |
| Quick Ratio | 9.347 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 9.982 | Overall short-term liquidity |
| Debt/Equity Ratio | 0.00% | Leverage ratio: Debt / Equity |
| EBITDA | $-146,439,008 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $14,337,000 | Total company revenue |
| Revenue per Share | $0.277 | Total revenue divided by shares outstanding |
| Gross Profit | 0.00% | Revenue minus cost of goods sold |
| Return on Assets | -15.39% | Net income / Total assets |
| Return on Equity | -427.47% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | -52.70% | Year-over-year revenue growth |
| Gross Margin | 0.00% | Gross profit / Total revenue |
| EBITDA Margin | 0.00% | EBITDA / Revenue |
| Operating Margin | -790.78% | Operating income / Revenue |
| Profit Margin | 0.00% | Net income / Revenue |
| Free Cash Flow | $-111,588,128 | Cash left after capital expenditures |
| Operating Cash Flow | $-173,436,992 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |